loader image
Friday, December 19, 2025
75.4 F
McAllen
- Advertisement -

FDA Approves Daily Pill to Treat Low Libido in Women After Menopause

Health & LifestyleNews
54

Listen to article (english)

Translate to Spanish or other 102 languages!

On December 15, 2025, the U.S. Food and Drug Administration (FDA) approved the medication Addyi (flibanserin) for the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women under the age of 65. Image for illustration purposes
On December 15, 2025, the U.S. Food and Drug Administration (FDA) approved the medication Addyi (flibanserin) for the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women under the age of 65. Image for illustration purposes

Mega Doctor News

- Advertisement -

Medical News Today

On December 15, 2025, the U.S. Food and Drug Administration (FDA) approved the medication Addyi (flibanserin) for the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women under the age of 65.

Addyi was previously approved in 2015 for the treatment of HSDD in premenopausal women. Premenopause or “before” menopause refers to the reproductive time in a cisgender woman’s life when they have regular menstrual cycles.

- Advertisement -

Follow the link below to Medical News Today to read the full story:

https://www.medicalnewstoday.com/articles/fda-approves-daily-pill-treat-low-libido-women-postmenopause-explainer?utm_term=feature&utm_source=Sailthru%20Email&utm_medium=Email&utm_campaign=MNT%20Daily%20News&utm_content=2025-12-19&apid=&rvid=4ba4ec80177cae00eabc43b8bc6648d598c4a356d104663735777e0a0f8b5c9f

Information source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
Heart Association Highlights 2025’s Major Research Findings

More Articles

Heart Association Highlights 2025’s Major Research Findings

In 2025, cardiovascular investigators worldwide reported findings that could help fill important gaps in preventing and managing conditions including high blood pressure, stroke, heart failure, dangerous blood clots and aortic stenosis.

DHR Health and Brownsville Join Forces on Major Hospital Expansion

The City of Brownsville and DHR Health announced a new public-private partnership to expand DHR Health Brownsville, marking a major investment in local healthcare and economic development

Uniting Experts to Revolutionize Cancer Treatment

More than 70% of all cancers are impacted by mutations caused by a group of DNA-editing enzymes that drives tumor growth and drug resistance. The apolipoprotein B mRNA-editing enzyme catalytic polypeptide, or APOBEC, family, is a dominant factor in many cancers including bladder, breast, cervical, head and neck and lung.

Early Findings Show Breast Cancer Vaccine Produces Immune Response

Cleveland Clinic released its findings from the first phase of the clinical trial for the preventive breast cancer vaccine. 
- Advertisement -

We feature articles about leading professionals in the medical and healthcare industry in the South Texas area. We are your connection to the medical community!

Pick up a copy of our publication on more than 800 locations Valley-wide.

Contact Us

Office (956) 928-1255

Sales (956) 451-4585

info@tbbmega.com

sales@tbbmega.com

Subscribe

© Mega Doctor News 2025

×